International Medical Center of Biomaterials Processing and Cryostorage (MISX:GEMA) - Share price, News & Analysis

GEMA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	3/6

GEMA Stock Overview

Rewards

Trading at 88.2% below our estimate of its fair value

Earnings have grown 6.7% per year over the past 5 years

Risk Analysis

Dividend of 12.39% is not well covered by earnings

Does not have meaningful revenue (RUB266M)

Does not have a meaningful market cap (RUB1B)

International Medical Center of Biomaterials Processing and Cryostorage Competitors

Price History & Performance

Summary of all time highs, changes and price drops for International Medical Center of Biomaterials Processing and Cryostorage
Historical stock prices
Current Share Price	₽698.00
52 Week High	₽1,250.00
52 Week Low	₽601.00
Beta	0.40
1 Month Change	2.20%
3 Month Change	-22.87%
1 Year Change	0.79%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.38%

Recent News & Updates

Jan 13

Is International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company's (MCX:GEMA) Latest Stock Performance A Reflection Of Its Financial Health?

Most readers would already be aware that International Medical Center of Biomaterials Processing and Cryostorage's...

Shareholder Returns

	GEMA	RU Healthcare	RU Market
7D	-2.2%	0.5%	1.5%
1Y	0.8%	-16.7%	-22.1%

Return vs Industry: GEMA exceeded the Russian Healthcare industry which returned -16.7% over the past year.

Return vs Market: GEMA exceeded the Russian Market which returned -22.1% over the past year.

Price Volatility

Is GEMA's price volatile compared to industry and market?
GEMA volatility
GEMA Average Weekly Movement	11.6%
Healthcare Industry Average Movement	5.5%
Market Average Movement	15.9%
10% most volatile stocks in RU Market	22.6%
10% least volatile stocks in RU Market	10.0%

Stable Share Price: GEMA is less volatile than 75% of Russian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: GEMA's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	23	n/a	https://www.gemabank.ru

International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company operates as a licensed bank for personal storage of cord blood stem cells in Russia and the CIS countries. The company is based in Moscow, Russia. International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company is a subsidiary of Human Stem Cells Institute PJSC.

International Medical Center of Biomaterials Processing and Cryostorage Fundamentals Summary

How do International Medical Center of Biomaterials Processing and Cryostorage's earnings and revenue compare to its market cap?
GEMA fundamental statistics
Market Cap	₽1.04b
Earnings (TTM)	₽136.50m
Revenue (TTM)	₽265.89m

7.6x

P/E Ratio

3.9x

P/S Ratio

Is GEMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GEMA income statement (TTM)
Revenue	₽265.89m
Cost of Revenue	₽42.24m
Gross Profit	₽223.65m
Other Expenses	₽87.15m
Earnings	₽136.50m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	91.43
Gross Margin	84.11%
Net Profit Margin	51.34%
Debt/Equity Ratio	14.9%

How did GEMA perform over the long term?

See historical performance and comparison

Dividends

12.4%

Current Dividend Yield

95%

Payout Ratio

Valuation

Is International Medical Center of Biomaterials Processing and Cryostorage undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: GEMA (RUB698) is trading below our estimate of fair value (RUB5904.17)

Significantly Below Fair Value: GEMA is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: GEMA is good value based on its PE Ratio (7.6x) compared to the European Healthcare industry average (19.3x).

PE vs Market: GEMA is poor value based on its PE Ratio (7.6x) compared to the Russian market (6.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GEMA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: GEMA is overvalued based on its PB Ratio (5.2x) compared to the XE Healthcare industry average (2x).

Future Growth

How is International Medical Center of Biomaterials Processing and Cryostorage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

13.4%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as International Medical Center of Biomaterials Processing and Cryostorage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has International Medical Center of Biomaterials Processing and Cryostorage performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

6.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GEMA has high quality earnings.

Growing Profit Margin: GEMA's current net profit margins (51.3%) are higher than last year (50.6%).

Past Earnings Growth Analysis

Earnings Trend: GEMA's earnings have grown by 6.7% per year over the past 5 years.

Accelerating Growth: GEMA's earnings growth over the past year (11.2%) exceeds its 5-year average (6.7% per year).

Earnings vs Industry: GEMA earnings growth over the past year (11.2%) underperformed the Healthcare industry 50.3%.

Return on Equity

High ROE: GEMA's Return on Equity (67.7%) is considered outstanding.

Financial Health

How is International Medical Center of Biomaterials Processing and Cryostorage's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: GEMA's short term assets (RUB590.5M) exceed its short term liabilities (RUB165.6M).

Long Term Liabilities: GEMA's short term assets (RUB590.5M) exceed its long term liabilities (RUB311.7M).

Debt to Equity History and Analysis

Debt Level: GEMA has more cash than its total debt.

Reducing Debt: GEMA's debt to equity ratio has increased from 0.01% to 14.9% over the past 5 years.

Debt Coverage: GEMA's debt is well covered by operating cash flow (810.6%).

Interest Coverage: GEMA earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is International Medical Center of Biomaterials Processing and Cryostorage current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

12.39%

Current Dividend Yield

Upcoming Dividend Payment

Dividend Yield vs Market

Notable Dividend: GEMA's dividend (12.39%) is higher than the bottom 25% of dividend payers in the Russian market (3.97%).

High Dividend: GEMA's dividend (12.39%) is in the top 25% of dividend payers in the Russian market (11.03%)

Stability and Growth of Payments

Stable Dividend: Too early to tell whether GEMA's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if GEMA's dividend payments are increasing as they only just started paying a dividend.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (94.6%), GEMA's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (54.2%), GEMA's dividend payments are covered by cash flows.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

International Medical Center of Biomaterials Processing and Cryostorage has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31